Literature DB >> 22236850

Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa.

A Dramowski1, M M Morsheimer, A M Jordaan, T C Victor, P R Donald, H S Schaaf.   

Abstract

SETTING: Tygerberg Children's Hospital (TCH) and Brooklyn Chest Hospital (BCH), South Africa.
OBJECTIVES: To describe paediatric cases of rifampicin (RMP) monoresistant tuberculosis (RMR-TB) disease.
DESIGN: Records of children with culture-confirmed RMR-TB between 1 March 2003 and 28 February 2009 were identified from a prospectively recorded database of drug-resistant TB at TCH and BCH. Mutation analysis was performed on available specimens.
RESULTS: Eighteen children with a median age of 6.9 years (range 2 months-12.8 years) were identified. Nine (50%) were human immunodeficiency virus (HIV) infected and four (22%) were HIV-exposed but non-infected. Eleven (61%) had had previous TB treatment or prophylaxis. Nine children (50%) had cavitary disease and five children (22%) had extra-pulmonary disease. Twelve (67%) had adult TB source cases, including five (42%) adults with known RMR-TB. Primary transmission occurred among 11 children (61%) and acquisition of RMR-TB was possible in seven (39%) with prior RMP exposure. Median delay to specific RMR-TB treatment was 70 days (range 23-188). One child died from RMR-TB meningitis. Gene mutations consistent with RMR-TB were confirmed in five available samples.
CONCLUSION: RMR-TB disease is increasingly encountered, particularly among HIV-infected and HIV-exposed non-infected children. Delay in commencing appropriate treatment for RMR-TB and high rates of cavitary disease could be a source of RMR-TB transmission.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22236850      PMCID: PMC5523943          DOI: 10.5588/ijtld.11.0360

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  27 in total

1.  Selective malabsorption and the origin of mono-rifampin-resistant Mycobacterium tuberculosis.

Authors:  D C Perlman; N Salomon
Journal:  Am J Respir Crit Care Med       Date:  1996-10       Impact factor: 21.405

2.  Childhood drug-resistant tuberculosis in the Western Cape Province of South Africa.

Authors:  H Simon Schaaf; Ben J Marais; Anneke C Hesseling; Robert P Gie; Nulda Beyers; Peter R Donald
Journal:  Acta Paediatr       Date:  2006-05       Impact factor: 2.299

3.  HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers.

Authors:  P Sonnenberg; J Murray; J R Glynn; S Shearer; B Kambashi; P Godfrey-Faussett
Journal:  Lancet       Date:  2001-11-17       Impact factor: 79.321

4.  Control of anti-tuberculosis drug resistance in Botswana.

Authors:  E A Talbot; T A Kenyon; M J Mwasekaga; T L Moeti; V Mallon; N J Binkin
Journal:  Int J Tuberc Lung Dis       Date:  2003-01       Impact factor: 2.373

5.  Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.

Authors:  F K Mukinda; D Theron; G D van der Spuy; K R Jacobson; M Roscher; E M Streicher; A Musekiwa; G J Coetzee; T C Victor; B J Marais; J B Nachega; R M Warren; H S Schaaf
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

6.  The impact of a change in bacille Calmette-Guérin vaccine policy on tuberculosis incidence in children in Cape Town, South Africa.

Authors:  Hassan Mahomed; Maurice Kibel; Tony Hawkridge; H Simon Schaaf; Willem A Hanekom; Karen Iloni; Desiré Michaels; Lesley Workman; Suzanne Verver; Lawrence Geiter; Gregory D Hussey
Journal:  Pediatr Infect Dis J       Date:  2006-12       Impact factor: 2.129

Review 7.  Global epidemiology of childhood tuberculosis.

Authors:  L J Nelson; C D Wells
Journal:  Int J Tuberc Lung Dis       Date:  2004-05       Impact factor: 2.373

8.  Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi: results of a drug resistance survey.

Authors:  M Sanders; A Van Deun; D Ntakirutimana; J P Masabo; J Rukundo; L Rigouts; K Fissette; F Portaelst
Journal:  Int J Tuberc Lung Dis       Date:  2006-02       Impact factor: 2.373

9.  Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.

Authors:  Richard E Nettles; Dana Mazo; Karla Alwood; Regina Gachuhi; Gina Maltas; Karen Wendel; Wendy Cronin; Nancy Hooper; William Bishai; Timothy R Sterling
Journal:  Clin Infect Dis       Date:  2004-02-17       Impact factor: 9.079

10.  Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases.

Authors:  H Simon Schaaf; Ben J Marais; Andrew Whitelaw; Anneke C Hesseling; Brian Eley; Gregory D Hussey; Peter R Donald
Journal:  BMC Infect Dis       Date:  2007-11-29       Impact factor: 3.090

View more
  15 in total

1.  Xpert Mycobacterium tuberculosis/Rifampicin-Detected Rifampicin Resistance is a Suboptimal Surrogate for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications.

Authors:  Bertin C Bisimwa; Jean B Nachega; Robin M Warren; Grant Theron; John Z Metcalfe; Maunank Shah; Andreas H Diacon; Nadia A Sam-Agudu; Marcel Yotebieng; André N H Bulabula; Patrick D M C Katoto; Jean-Paul Chirambiza; Rosette Nyota; Freddy M Birembano; Eric M Musafiri; Sifa Byadunia; Esto Bahizire; Michel K Kaswa; Steven Callens; Zacharie M Kashongwe
Journal:  Clin Infect Dis       Date:  2021-07-15       Impact factor: 9.079

2.  True facets of TB diagnosis in 2012: Hypes and realities.

Authors:  S K Parida
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-12-11

3.  Next-Generation Sequencing for Characterizing Drug Resistance-Conferring Mycobacterium tuberculosis Genes from Clinical Isolates in the Ukraine.

Authors:  L T Daum; O S Konstantynovska; O S Solodiankin; O O Liashenko; P I Poteiko; V I Bolotin; I I Hrek; A V Rohozhyn; J D Rodriguez; G W Fischer; J P Chambers; A P Gerilovych
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

4.  Characterization of W-Beijing isolates of Mycobacterium tuberculosis from the Western Cape.

Authors:  Crystal A Shanley; Elizma M Streicher; Robin M Warren; Thomas C Victor; Ian M Orme
Journal:  Vaccine       Date:  2013-10-19       Impact factor: 3.641

5.  Xpert(®) MTB/RIF detection of rifampin resistance and time to treatment initiation in Harare, Zimbabwe.

Authors:  J Z Metcalfe; S Makumbirofa; B Makamure; C Sandy; W Bara; P Mason; P C Hopewell
Journal:  Int J Tuberc Lung Dis       Date:  2016-07       Impact factor: 2.373

6.  Rifampin monoresistant tuberculosis and HIV comorbidity in California, 1993-2008: a retrospective cohort study.

Authors:  Lisa M Prach; Lisa Pascopella; Pennan M Barry; Jennifer Flood; Travis C Porco; Philip C Hopewell; John Z Metcalfe
Journal:  AIDS       Date:  2013-10-23       Impact factor: 4.177

7.  Rifampin-resistant Tuberculosis in the United States, 1998-2014.

Authors:  Lisa Sharling; Suzanne M Marks; Michael Goodman; Terence Chorba; Sundari Mase
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

8.  Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis.

Authors:  Vanina Meyssonnier; Thuy Van Bui; Nicolas Veziris; Vincent Jarlier; Jérôme Robert
Journal:  BMC Infect Dis       Date:  2014-01-10       Impact factor: 3.090

Review 9.  Towards early inclusion of children in tuberculosis drugs trials: a consensus statement.

Authors:  Sharon Nachman; Amina Ahmed; Farhana Amanullah; Mercedes C Becerra; Radu Botgros; Grania Brigden; Renee Browning; Elizabeth Gardiner; Richard Hafner; Anneke Hesseling; Cleotilde How; Patrick Jean-Philippe; Erica Lessem; Mamodikoe Makhene; Nontombi Mbelle; Ben Marais; Helen McIlleron; David F McNeeley; Carl Mendel; Stephen Murray; Eileen Navarro; E Gloria Anyalechi; Ariel R Porcalla; Clydette Powell; Mair Powell; Mona Rigaud; Vanessa Rouzier; Pearl Samson; H Simon Schaaf; Seema Shah; Jeff Starke; Soumya Swaminathan; Eric Wobudeya; Carol Worrell
Journal:  Lancet Infect Dis       Date:  2015-05-06       Impact factor: 25.071

10.  Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region.

Authors:  Yacoob Mahomed Coovadia; Sharana Mahomed; Melendhran Pillay; Lise Werner; Koleka Mlisana
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.